Zaiqi Wang, InxMed CEO

Chi­na biotech In­xMed bags $19M Se­ries A+ to de­vel­op PhI FAK in­hibitor

Near­ly a year af­ter Nan­jing, Chi­na-based In­xMed bagged its first-ever IND ap­proval, the com­pa­ny has raked in ¥130 mil­lion (about $19 mil­lion) in a Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.